ReviewInternational journal of environmental research and public health2020
Broadening and Enhancing Bacteriocins Activities by Association with Bioactive Substances.
Review in International journal of environmental research and public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Anticancer Potential of Antimicrobial Peptides: Mechanisms, Clinical Application, Challenges, and Future Prospects.Drug development research · 2026Review
- Structural and functional insights into lactobacin A: a novel non-pediocin-like bacteriocin from aMicrobiology spectrum · 2026Article
- Synthesis, Characterization, and Biomedical Applications of Bacteriocin-Selenium Nanoconjugates.Probiotics and antimicrobial proteins · 2025Article
- Antimicrobial Efficacy of Calcium Hydroxide Nanoparticles Combined with Nisin Against Enterococcus Faecalis in Root Canal Infections ��� an Ex Vivo Study.European endodontic journal · 2025Article
- Amino Acid Substitutions in Bacteriocin Lactolisterin BU Reveal Functional Domains Involved in Biological Activity AgainstMolecules (Basel, Switzerland) · 2025Article
- Pharmacological composition based on bacteriocinnisin in experimentsOpen veterinary journal · 2024Article
- Suppression of planktonic and biofilm of Escherichia coli by the synergistic lantibiotics-polymyxins combinations.Archives of microbiology · 2024Article
- Optimization of culture conditions for endophytic bacteria in mangrove plants and isolation and identification of bacteriocin.Frontiers in pharmacology · 2024Article
- Biopreservation of Food Using Bacteriocins From Lactic Acid Bacteria: Classification, Mechanisms, and Commercial Applications.International journal of microbiology · 2024Review
- Bioprospecting the Skin Microbiome: Advances in Therapeutics and Personal Care Products.Microorganisms · 2023Review
- A Review on Enterocin DD14, the Leaderless Two-Peptide Bacteriocin with Multiple Biological Functions and Unusual Transport Pathway.Antibiotics (Basel, Switzerland) · 2023Review
- Effect of Nanoemulsion Containing Enterocin GR17 and Cinnamaldehyde on Microbiological, Physicochemical and Sensory Properties and Shelf Life of Liquid-Smoked Salmon Fillets.Foods (Basel, Switzerland) · 2022Article
- Lacticaseicin 30 and Colistin as a Promising Antibiotic Formulation against Gram-Negative β-Lactamase-Producing Strains and Colistin-Resistant Strains.Antibiotics (Basel, Switzerland) · 2021Article
- Current Knowledge of the Mode of Action and Immunity Mechanisms of LAB-Bacteriocins.Microorganisms · 2021Review
- Alginate Nanoparticles Enhance Anti-Clostridium perfringens Activity of the Leaderless Two-Peptide Enterocin DD14 and Affect Expression of Some Virulence Factors.Probiotics and antimicrobial proteins · 2021Article
- A bacteriocin-based treatment option for Staphylococcus haemolyticus biofilms.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriocins are antimicrobial peptides some of which are endowed with antiviral, anticancer and antibiofilm properties. These properties could be improved through synergistic interactions of these bacteriocins with other bioactive molecules such as antibiotics, phages, nanoparticles and essential oils. A number of studies are steadily reporting the effects of these combinations as new and potential therapeutic strategies in the future, as they may offer many incentives over existing therapies. In particular, bacteriocins can benefit from combination with nanoparticles which can improve their stability and solubility, and protect them from enzymatic degradation, reduce their interactions with other molecules and improve their bioavailability. Furthermore, the combination of bacteriocins with other antimicrobials is foreseen as a way to reduce the development of antibiotic resistance due to the involvement of several modes of action. Another relevant advantage of these synergistic combinations is that it decreases the concentration of each antimicrobial component, thereby reducing their side effects such as their toxicity. In addition, combination can extend the utility of bacteriocins as antiviral or anticancer agents. Thus, in this review, we report and discuss the synergistic effects of bacteriocin combinations as medicines, and also for other diverse applications including, antiviral, antispoilage, anticancer and antibiofilms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.